Phenotypes associated with this allele

• Allele Symbol: Stk11^tm1.1Sjm
• Allele Name: targeted mutation 1.1, Sean J Morrison
• Allele ID: MGI:4440829
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Stk11^tm1.1Sjm/Stk11^tm1.1Sjm Ndor1^Tg(UBC-cre/ERT2)1Ejb/0	involves: 129S/SvEv * C57BL/6 * SJL	MGI:4840218
cn2	Stk11^tm1.1Sjm/Stk11^tm1.1Sjm Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA * SJL	MGI:4840221

Genotype
MGI:4840218

cn1

• Allelic Composition: Stk11^tm1.1Sjm/Stk11^tm1.1Sjm; Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0
• Genetic Background: involves: 129S/SvEv * C57BL/6 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

abnormal bone marrow cell physiology ( J:165090 )

• hematopoietic stem cells from doxycycline-treated mice fail to exhibit long-term reconstitution unlike wild-type cells

Genotype
MGI:4840221

cn2

• Allelic Composition: Stk11^tm1.1Sjm/Stk11^tm1.1Sjm; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA * SJL

hematopoietic system

thymus hypoplasia ( J:165090 )

• in pIpC-treated mice

abnormal bone marrow cell morphology/development ( J:165090 )

• following pIpC treatment, multipotent progenitors transiently expand then are depleted in parallel with hematopoietic stem cells unlike in Stk11^tm1Sjm homozygotes

decreased bone marrow cell number ( J:165090 )

• in pIpC-treated mice

decreased erythrocyte cell number ( J:165090 )

• in pIpC-treated mice

thrombocytopenia ( J:165090 )

• in pIpC-treated mice

decreased leukocyte cell number ( J:165090 )

• in pIpC-treated mice

decreased hematopoietic stem cell number ( J:165090 )

• 18 days after pIpC treatment; not improved by rapamycin treatment

pancytopenia ( J:165090 )

• by day 24 to 34 of pIpC treatment

increased hematopoietic stem cell number ( J:165090 )

• starting 2 to 6 days after pIpC treatment

abnormal bone marrow cell physiology ( J:165090 )

• hematopoietic stem cells (HSCs)from pIpC-treated mice exhibit increased cell proliferation compared with cells from Stk11^tm1Sjm homozygotes

• 11 days after pIpC-treatment, HSCs exhibit increased apoptosis compared with cells from Stk11^tm1Sjm homozygotes

• HSCs from pIpC-treated mice fail to exhibit long-term reconstitution unlike cells from Stk11^tm1Sjm homozygotes

• however, mice exhibit normal proliferation of granulocyte macrophage progenitors (GMP) and whole bone marrow (WBM) cells and apoptosis of multipotent progenitor, GMP, and WBM cells

cellular

cellular phenotype ( J:165090 )

N • hematopoietic stem cells from pIpC treated mice exhibit normal reactive oxygen species

aneuploidy ( J:165090 )

• hematopoietic stem cells from pIpC-treated mice become aneuploid unlike similarly treated cells from Stk11^tm1Sjm homozygotes

• however, granulocyte macrophage progenitors cells from pIpC-treated mice do not become aneuploid

abnormal mitotic spindle morphology ( J:165090 )

• hematopoietic stem cells from pIpC-treated mice exhibit supernumerary centrosomes and defective mitotic spindle unlike in cells from similarly treated Stk11^tm1Sjm homozygotes

increased mitochondrial fission ( J:165090 )

• in the hematopoietic stem cells of pIpC-treated mice

immune system

thymus hypoplasia ( J:165090 )

• in pIpC-treated mice

decreased leukocyte cell number ( J:165090 )

• in pIpC-treated mice

endocrine/exocrine glands

thymus hypoplasia ( J:165090 )

• in pIpC-treated mice